Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
8.12
-0.16 (-1.93%)
At close: May 9, 2025, 4:00 PM
8.12
0.00 (0.00%)
After-hours: May 9, 2025, 7:57 PM EDT
Intellia Therapeutics Stock Forecast
Stock Price Forecast
According to 19 professional analysts, the 12-month price target for Intellia Therapeutics stock ranges from a low of $10 to a high of $90. The average price target of $38.26 forecasts a 371.18% increase in the stock price over the next year.
Price Target: $38.26 (+371.18%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Intellia Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 6 | 6 |
| Buy | 7 | 7 | 6 | 6 | 7 | 7 |
| Hold | 5 | 6 | 6 | 6 | 6 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 18 | 17 | 18 | 19 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Hold Maintains $14 → $10 | Hold | Maintains | $14 → $10 | +23.15% | May 9, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $68 | Strong Buy | Maintains | $68 | +737.44% | May 9, 2025 |
| Wolfe Research | Wolfe Research | Hold → Buy Upgrades $21 | Hold → Buy | Upgrades | $21 | +158.62% | Apr 21, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $30 | Strong Buy | Initiates | $30 | +269.46% | Mar 5, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $90 → $50 | Strong Buy | Maintains | $90 → $50 | +515.76% | Mar 4, 2025 |
Financial Forecast
Revenue This Year
53.14M
from 57.88M
Decreased by -8.19%
Revenue Next Year
48.77M
from 53.14M
Decreased by -8.21%
EPS This Year
-4.81
from -5.25
EPS Next Year
-4.65
from -4.81
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 220.5M | 105.0M | 4.0B | ||
| Avg | 53.1M | 48.8M | 415.6M | ||
| Low | n/a | 6.9M | 3.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 281.0% | 97.6% | 8,052.1% | ||
| Avg | -8.2% | -8.2% | 752.2% | ||
| Low | - | -87.1% | -92.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.35 | -3.03 | -3.06 | ||
| Avg | -4.81 | -4.65 | -4.10 | ||
| Low | -5.60 | -5.60 | -5.08 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.